Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR).
Mross K, Scheulen ME, Licht T, Unger C, Richly H, Stern AC, Kutz K, Camboni MG, Barbieri P, Verdi E, Vincenzi B, Bernareggi A. Mross K, et al. Among authors: richly h. Anticancer Drugs. 2004 Jan;15(1):15-22. doi: 10.1097/00001813-200401000-00003. Anticancer Drugs. 2004. PMID: 15090738 Clinical Trial.
A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors.
Mross K, Richly H, Schleucher N, Korfee S, Tewes M, Scheulen ME, Seeber S, Beinert T, Schweigert M, Sauer U, Unger C, Behringer D, Brendel E, Haase CG, Voliotis D, Strumberg D. Mross K, et al. Among authors: richly h. Ann Oncol. 2004 Aug;15(8):1284-94. doi: 10.1093/annonc/mdh313. Ann Oncol. 2004. PMID: 15277271 Free article. Clinical Trial.
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Strumberg D, et al. Among authors: richly h. J Clin Oncol. 2005 Feb 10;23(5):965-72. doi: 10.1200/JCO.2005.06.124. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613696 Clinical Trial.
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K, Hilger RA, Scheulen ME, Christensen O, Brendel E, Schwartz B, Hofstra E, Voigtmann R, Seeber S, Strumberg D. Kupsch P, et al. Among authors: richly h. Clin Colorectal Cancer. 2005 Sep;5(3):188-96. doi: 10.3816/ccc.2005.n.030. Clin Colorectal Cancer. 2005. PMID: 16197622 Clinical Trial.
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K. Strumberg D, et al. Among authors: richly h. Br J Cancer. 2012 May 22;106(11):1722-7. doi: 10.1038/bjc.2012.153. Epub 2012 May 8. Br J Cancer. 2012. PMID: 22568966 Free PMC article. Clinical Trial.
The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology.
Müller HJ, Grubert M, Hilger R, Richly H, Port R, Scheulen M, Mross K; CESAR-APOH. Müller HJ, et al. Among authors: richly h. Int J Clin Pharmacol Ther. 2002 Dec;40(12):575-7. doi: 10.5414/cpp40575. Int J Clin Pharmacol Ther. 2002. PMID: 12503820 Clinical Trial. No abstract available.
64 results